Phase 3 N=29 Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
Raynaud Phenomenon
Primary: RP Attacks Per Day — -0.5; -0.5 attacks per day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=514 Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
Parkinson's Disease
Primary: The Change in the Absolute Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary — -1.948; -2.052; -2.138…
Phase 3 N=3,366 Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
Arthritis, Rheumatoid
Primary: Number of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response at Month 6 — 2692 Participants
Phase 3 N=252 Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock
Septic Shock
Primary: Efficacy and Safety of Dopamine Versus Norepinephrine in Septic Shock — 67; 51 participants
Phase 3 N=51 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Eosinophilic Esophagitis · Gastroesophageal Reflux Disease · EE
Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00
Phase 3 N=45 Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
Crohn's Disease
Primary: Median Crohn's Disease Activity Index (CDAI) Change From Week 0 to Week 8 in the Increased Dose Period — 95.0 units on a scale
Phase 3 N=2,004 Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
Encephalitis · Japanese Encephalitis
Primary: Number of Participants Reporting Treatment Related Adverse Events Post Vaccination With Either ChimeriVax™-JE or a Placebo — 90; 365; 69; 297 Participants
Phase 3 N=820 A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX
Japanese Encephalitis
Primary: Number of Participants With Japanese Encephalitis (Homologous Virus) Seroconversion Following Either ChimeriVax™-JE or JE-Vax® Vaccination — NA; 324; 273; 343 Participants
Phase 3 N=1,735 Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission
Disease Transmission, Vertical · Vertical Human Immunodeficiency Virus Transmission · HIV Infections
Primary: Infant HIV Infection Status — 24; 11; 12 participants — p=.046
Phase 3 N=811 A Study in Painful Diabetic Neuropathy
Diabetic Neuropathy, Painful
Primary: Change From Week 8 to Week 16 Endpoint in 24 Hour Average Pain Item Score on the Brief Pain Inventory (BPI) Modified Short Form — -2.353; -2.161 units on a scale — p=0.370
Phase 3 N=2,710 Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
Colon Adenocarcinoma · Stage IIA Colon Cancer AJCC v7 · Stage IIB Colon Cancer AJCC v7
Primary: Disease-free Survival — 75.5; 77.4 percentage of patients
Phase 3 N=58 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
Gastroparesis
Primary: Symptom of Vomiting Associated With Gastroparesis — 1.82; 2.68; 0.17; 1.20 Patient Self-reported Symptom Score
Phase 3 N=39 The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
Major Depression · Bipolar Depression · Schizoaffective Disorder
Primary: Number of Side Effects — 19; 13 Number of reported side effects
Phase 3 N=2,120 Confirmatory Study Nepafenac 0.3%
Cataract
Primary: Percentage of Patients Cured at Day 14 — 68.4; 70.0; 34.0; 35.6 percentage of participants
Phase 3 N=42 Trial of Mifepristone for Fibroids
Leiomyoma
Primary: Uterine Volume — 719; 449 mL